Zotefoams says sales meeting expectations
Zotefoams, which manufactures and sells high-performance foams, said on Wednesday its business has continued to perform in line with expectations following sales growth in 2012.
Zotefoams, which manufactures and sells high-performance foams, said on Wednesday its business has continued to perform in line with expectations following sales growth in 2012.
Ahead of preliminary results for the year ended December 31st 2012, the company said it expected an annual sales growth of 6%.
The firm also reported an 8% increase in fourth quarter sales, compared to the same period the year before.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The high-performance polymers (HPP) business accounted for half the sales increase for the year. Results were also driven by sales in the Azote polyolefin foams business, which climbed 3%.
"The board therefore remains confident of an outcome for 2012 in line with market expectations," the company said in a statement.
Zotefoams gained 0.25% to 203.50p at 9:37 following the trading update. Annual results will be released on March 5th.
RD
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Going part-time could leave a £58,000 hole in your pension: how to plug the gap
There are many reasons for switching to part-time work, but some savers don’t consider the impact on their pension until it is too late
By Katie Williams Published
-
Three bargain investment trusts to add to your portfolio
These three investment trusts are bargains compared to their net asset value (NAV), but one fund analyst thinks the deep discounts are unwarranted.
By Dan McEvoy Published